A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies.

Inclusion Criteria: * Adult subjects (18 years and older) with histologically or cytologically of advanced (metastatic or inoperable) advanced solid tumors. * Tumor (either an archival specimen or a fresh biopsy) shows NY-ESO-1 expression of 1+ by IHC (H-score). NY-ESO-1 expression must be confirmed by central validated assay. * Patients with NY-ESO-1 expressing solid tumors will be included. Patients must have received, been intolerant of, or been ineligible to receive at least 2 lines of the current standard of care therapy including but not limited to chemotherapy, immunotherapy and/or targeted therapy when appropriate (e.g. Atezolizumab is approved for use in patients with alveolar soft part sarcoma) according to their disease: * Inoperable or metastatic (advanced) ovarian, primary peritoneal or fallopian tube carcinoma: * Has received platinum containing chemotherapy and has platinum refractory or resistant disease that has progressed on second line therapy * If platinum sensitive disease, should have received ≥2 lines of chemotherapy. * May have received PARP inhibitors, bevacizumab or other targeted VEGF inhibitor therapy * Inoperable or metastatic (advanced) soft tissue sarcoma: * Subjects must have previously received either an anthracycline or ifosfamide containing regimen. * Gastrointestinal stromal tumors are eligible, but only must have previously received KIT-targeted therapy if a sensitizing mutation is present. * Angiosarcomas are eligible, but only must have received prior taxane-based chemotherapy * Urothelial carcinoma: * Subjects must have received or refused 1 prior platinum-based therapy for the treatment of metastatic or locally advanced unresectable disease. * Subjects who are not eligible for a platinum-containing regimen or who have progressed on a platinum-containing regimen * Subjects may have received an anti-PD-l/PDL1 checkpoint inhibitor * Metastatic castration-resistant adenocarcinoma of the prostate (CRPC) defined as serum testosterone level ≤ 50 ng/dL with prior surgical castration or ongoing androgen deprivation, with progressive disease: * Progressive disease is defined by rising prostate specific antigen (PSA) or radiographic imaging according to the PCWG3 criteria during or following the direct prior line of therapy in the setting of medical or surgical castration * At least one prior chemotherapy regimen in the metastatic setting * Prior therapy with at least one standard 17α lyase inhibitor or second generation anti-androgen therapy for the treatment of castrate- resistant prostate cancer. * Breast Cancer * Prior standard of care regimens with at least one anthracycline or taxane-based regimen in either an adjuvant or metastatic setting unless intolerant or clinically not indicated. For ER positive HER2 negative cancer must have progressed on therapy with CDK 4/6 inhibitor combination. Prior hormonal therapy or Human epidermal growth factor receptor-2 (HER2) targeted therapies are allowed. * Melanoma * A PD-1 or PD-L1 inhibitor (with or without a cytotoxic T lymphocyte-associated protein 4 \[CTLA-4\] inhibitor). Patients with an actionable mutation (e.g., BRAF) must have received at least one targeted therapy. * Non-small cell lung cancer * A PD-1 or PD-L1 inhibitor and for patients with a PD-L1 tumor proportion score (TPS) \< 50%, a platinum-based chemotherapy regimen. Patients with non-squamous NSCLC with an actionable mutation (e.g., EGFR, ALK, ROS-1) must have received at least one targeted therapy. A checkpoint inhibitor is not required for patients with actionable mutations. * Additional advanced solid tumor expressing NY-ESO-1 are included. Patients must have received a minimum of one prior therapy. * Subjects who are intolerant to required prior therapies must have previously received at least one systemic therapy that was deemed ineffective by the treating physician. * At screening, must have tissue available for NY-ESO-1 testing (if not previously performed) or be willing and able to undergo a fresh tissue biopsy. * HLA-A\*0201 (HLA-A2.1) positivity by molecular subtyping (blood test or buccal swab, historical documentation acceptable). * Age ≥ 18 years old. * Life expectancy greater than 3 months assessed by a study physician. * Have been informed of other treatment options. * A minimum of one measurable lesion defined as meeting the criteria for measurable disease according RECIST1.1 criteria. * No restriction based on prior treatments provided they have discontinued therapy at least 4 weeks prior to starting study treatment. Lesions amenable to radiotherapy or palliative radiotherapy (e.g.- bone metastases or metastases causing nerve impingement) should be treated \> 4 weeks prior to enrollment and patients must be fully recovered from the effects of radiation prior to receiving the investigational agent and that patients must not receive radiation while enrolled on this study. * Patients must have received prior anti-cancer treatment(s) or an investigational product(s) within 28 days or 5 half-lives, whichever is longer, prior to the first dose of study treatment(s) AND unresolved or unstable serious toxic side-effects of prior chemotherapy/treatment must have recovered to Grade 1 per CTCAE (v5.0) * Must have adequate venous access for apheresis and must be willing to and able to go through the procedure. * Women of childbearing potential must agree to use effective methods of birth control for the duration of the study and 6 to 12 months after until persistence of the study drug is no longer detected in the peripheral blood. Methods for acceptable birth control include: condoms, diaphragm or cervical cap with spermicide, intrauterine device, and hormonal contraception. It is recommended that a combination of two methods be used. * ECOG performance status ≤1 (Karnofsky ≥80%, see Appendix A). * Patients must have normal organ and marrow function as defined below: * leukocytes ≥3,000/mcL * absolute neutrophil count ≥1,000/mcL * platele